Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

Mindler has taken ownership of the UK company, which has been providing digitally delivered talking therapies to the NHS for ...

"We are, of course, disappointed by the FDA's decision to not approve vatiquinone," said Matthew Klein, PTC's chief executive ...

Among the plans will be greater first-line use of SGLT-2 inhibitors or 'gliflozin' drugs, which are mainly used second-line ...

In the world of consumer marketing, people-based data has become the gold standard. Demographics are just the starting point. Layered on top are deep behavioural insights into what people buy, browse, ...

The decision to demerge the CSL Seqirus business into a separate ASX-listed company will allow it to "set an independent ...

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...

Developing treatments for rare diseases poses many unique challenges that cannot be addressed by traditional study designs.

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose ...

And while pharma marketing agencies are embracing AI like everyone else, most are using AI tools on a case-by-case basis to tackle one or more of those areas. But what if an agency were to redesign ...

It is in the shadow of these changes that the 7th Cell Therapy Analytical Development Summit returns to unite the field.

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the ...